Browse > Article

Leptomycin B Increases Radiosensitization by Trichostain A in HeLa Cells  

Kim, In-An (Department of Radiation Oncology, Cancer Research institute, Seoul National University College of Medicine, Department of Radiation Oncology, Seoul National University Bundang Hospital)
Kim, Jin-Ho (Department of Radiation Oncology, Cancer Research Institute, Seoul National University College of Medicine)
Shin, Jin-Hee (Department of Radiation Oncology, Cancer Research Institute, Seoul National University College of Medicine)
Kim, Il-Han (Department of Radiation Oncology, Cancer Research Institute, Institute of Radiation medicine, Seoul National University College of Medicine)
Kim, Jae-Sung (Department of Radiation Oncology, Cancer Research Institute, Department of Radiation Oncology, Seoul National University Bundang Hospital)
Wu-Hong, Gyun (Department of Radiation Oncology, Cancer Research Institute, Institute of Radiation medicine, Seoul National University College of Medicine)
Chie, Eui-Kyu (Department of Radiation Oncology, Cancer Research Institute, Seoul National University College of Medicine)
Kim, Yong-Ho (Department of Radiation Oncology, Seoul National University College of Medicine, Department of Radiation Oncology, Soonchunhyang University Hospital)
Kim, Bo-Kyung (Department of Radiation Oncology, Seoul National University College of Medicine, Department of Radiation Oncology, Dankook University Hospital)
Hong, Se-Mie (Department of Radiation Oncology, Seoul National University College of Medicine, Department of Radiation Oncology, Konkuk University Hospital)
Ha, Sung-Whan (Department of Radiation Oncology, Institute of Radiation Medicine, Seoul National University College of Medicine)
Park, Chan-Il (Department of Radiation Oncology, Institute of Radiation Medicine, Seoul National University College of Medicine)
Publication Information
Radiation Oncology Journal / v.23, no.2, 2005 , pp. 116-122 More about this Journal
Abstract
Purpose: Histone deacetylase inhibitors (HDIs) are emerging as potentially useful components of anticancer therapy and their radiosensitizing effects have become evident. Specific HDAS are now available that preferentially inhibit specific HDAC classes; TSA inhibits Class I and II HDACs, and SK7041 inhibits Class I HDACs. Materials and methods: We tested the differential radiosensitization induced by two different classes of HDIs in HeLa cells. We next tested the hypothesis that p53 expression in cancer cells may influence the susceptibility to HDIs by using pharmacologic modification of the p53 status under an isogenic background. Results: It is interesting that p53 expression in the HeLa cells clearly increased the degree of radio-sensitization by TSA compared to that of the class I specific inhibitor SK7041. This suggests that p53 may, in part, be responsible for the mechanistic role for the greater radiosensitization induced by Class I & II inhibitors compared to that of the class I specific inhibitors. Thus, these studies are useful in distinguishing between events mediated solely by the Class I HDACS versus those events involving the other classes of HDACS as well. Conclusion: The anticancer efficacy of targeting Class I and II HDACS, in conjunction with radiation therapy, may be further enhanced by the restoration of p53 expression.
Keywords
Histone deacelylase inhibitor; Radiosensitization; Leplomycin B; p53;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216   DOI   ScienceOn
2 Antonelllo Mai, Silvio Massa, Dante Rotili, et al. Histone Deacetylation in Epigenetics: An attractive target for anticancer therapy. Medicinal Research Rev 2005;25:261-309   DOI   ScienceOn
3 Park JH, Jung Y, Kim TY, et al. Class I histone deacetyalse-selective novel synthetic inhibitors potentially inhibit human tumor proliferation. Clin Cancer Res 2004;10:5271- 5281   DOI   ScienceOn
4 Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of death receptor pathway. Nat Med 2005;11:71-76   DOI   ScienceOn
5 Bakin RE, Jung MO. Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. J Biol Chem 2004;279:51218-51225   DOI   ScienceOn
6 Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997;57:3697-3707
7 Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 2003;160:1017-1027   DOI   ScienceOn
8 Schwartz JL, Russell KJ. The effect of functional inactivation of TP53 by HPV-E6 transformation on the induction of chromosome aberration by gamma rays in human tumor cells. Radiat Res 1999;151:385-390   DOI   ScienceOn
9 Schwartz JL, Jordan R, Kaufmann WK, et al. Evidence for the expression of radiation-induced petetially lethral damage being a p53-dependent process. Int J Radiat Biol 2000;76:1037-1043   DOI   ScienceOn
10 Ito A, Lai CH, Zhao X, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001;20:1331-1340   DOI   ScienceOn
11 Glaser KJ, Li J, Staver RQ, et al. Role of class I and Class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Comm 2003;310:529-536   DOI   ScienceOn
12 Joseph J, Wajapeyee N, Somasundaram K. Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate. Int J Cancer 2005;115:11-18   DOI   ScienceOn
13 Kubbuttat MH, Jones SN, Vousden KH. Regulation of p53 stability by mdm2. Nature 1997;387:299-303   DOI   ScienceOn
14 Hietanen S, Lain S, Krausz E, et al. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 2000;97:8501-8506   DOI
15 Liang SH, Clarke MF. Regulation of p53 localization. Eur J Biochem 2001;268:2779-2783   DOI   ScienceOn
16 Lain S, Xirodima D, Lain DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell Res 1999;253:315-324   DOI   PUBMED   ScienceOn
17 Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of $\gamma$H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64:316-321   DOI   ScienceOn
18 Kudo N, Wolff B, Sekimoto T, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 1998;242:540-547   DOI   ScienceOn
19 Vaziri H, Dessain SK, Ng Eaton E, et al. $hSIR2^{SIRT1}$ functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159   DOI   ScienceOn
20 Camphausen K, Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft radiosenstivity by histone deacetylase inhibitor MS275 and Correlation with histone hyperacetylation. Clin Cancer Res 2004;10:6066-6071   DOI   ScienceOn
21 Kim IA, Yang YJ, Yoon SC, et al. Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas. Int J Oncol 2001;19:1041-1047
22 Biade S, Stobbe CC, Boyd JT, Chapman JD. Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 2001;77:1033-1042   DOI   ScienceOn
23 Luo J, Li M, Tang Y, et al. Acetylaton of p53 augments its site-specific DNA bind both in vitro and in vivo. Proc Natl Acad Sci USA 2004;101:2259-2264   DOI
24 Nakamura S, Roth JA, Mukhopadhyay T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 2000;20:9391-9398   DOI   ScienceOn
25 Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylase related to yeast Hda1p. Proc Natl Acad Sci USA 1999;96:4868-4873   DOI
26 Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000;408:377-381   DOI   ScienceOn
27 Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001;1:194-202   DOI   ScienceOn
28 Yang XY, Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Nev 2003;13:143-153   DOI   ScienceOn
29 Bernstein BT, Tong T, Schreiber S. Genomwide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 2000;97:13708-13713   DOI   ScienceOn
30 Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999;19:1202-1209   DOI
31 Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005;25:552-563
32 Fische W, Kiermer V, Dequiedt F, et al. The emerging role of class II histone deactylase. Biochem Cell Biol 2001;79:339-348
33 Liu F, Dowling M, Yang XJ, Kao GD. Caspase-mediated specific cleavage of human histone deacetylase 4. J Biol Chem 2004;13:34537-34546   DOI   ScienceOn
34 Thiagalingam S, Cheng KH, Lee HJ, Minerva NA. Histone deactylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003;983:84-100   DOI   PUBMED   ScienceOn
35 Bristow RG, Benchimol S, Hill RP. The 53 gene as a modifier of intrinsic radiosensitivity: implication for radiotherapy. Radiotherapy and Oncology 1996;40:197-223   DOI   ScienceOn
36 Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003;278:12579-12589   DOI   ScienceOn
37 Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death & Differentiation. Advance online publication Mar 2005;cdd4401581   DOI   ScienceOn
38 Lain DP, Lain S. Therapeutic exploration of the p53 pathway. Trends Mol Med 2002;8:S38-S42   DOI   PUBMED   ScienceOn
39 Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262:75-83   DOI   ScienceOn
40 Kudo N, Matsumori N, Taoka H, et al. Leptomycin B inactivates CRM1/expotin 1 by covalent modification at a cystein residue in the central conserved region. Proc Natl Acad Sci USA 1999.96:9112-9117   DOI   ScienceOn
41 Grunstein M. Histone acetylation and chromatin structure and transcription. Nature 1997;389:349-352   DOI   PUBMED   ScienceOn
42 Bertos NR, Wang AH, Yang XY. Class II histone deacetylase: Structure, function, and regulation. Biochem Cell Biol 2001;79:243-252   DOI   ScienceOn
43 Honda R, Tanaka H, Yasuda H. Oncoprotein mdm2 is ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-27   DOI   ScienceOn
44 Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004;62:1348-1354
45 Nebbiosso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84   DOI   ScienceOn
46 Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2$\alpha$ promotes cell survival under stress. Cell 2001;107:137-148   DOI   PUBMED   ScienceOn
47 Kim JH, Shin JH, Chie EK, et al. Trichostatin A, a histone deacetylase inhibitor, potentiated cytotoxic effect of inonizing radiation in human head and neck cancer cell lines. J Korean Soc Ther Radiol Oncol 2004:22:138-144
48 Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by mdm2. J Biol Chem 2002;277:50607-50611   DOI   ScienceOn